Mazen Ahmad
Philippe Moingeon
Philippe MOINGEON received his PhD in immunology from Paris XI University, and an MBA from Open University Business School (Newcastle, UK). He was formerly Resident of Paris Hospitals (1981-1986), Post-doctoral fellow (1987-1990) and Assistant Professor (1991-1994) at the Dana Farber Cancer Institute, Department of Pathology, Harvard Medical School (Boston, USA).
Philippe has extensive experience in the development of biologicals, holding several positions in the vaccine industry, including Head of the Cancer Vaccine program and General Secretary for Research and Development, at Aventis Pasteur (1994-2003), as well as Senior Vice President, Research and Pharmaceutical Development at Stallergenes (2003-2017). He joined Servier in September 2017, to head the Center for Therapeutic Innovation for immuno-inflammatory diseases.
Two vaccines registered in Europe, USA and Japan, 230 scientific publications in peer-reviewed journals, 23 patents/ patent applications.
Current scientific interests: artificial intelligence and computational modelling in support of drug development; applications to auto-immune, inflammatory and neurological diseases.
Richard Lewis
Richard A. Lewis is Director, Data Science at Novartis in Basel with interests in cheminformatics, ML, AI and generative chemistry. He earned his B.A. and Ph.D. from Cambridge University. He performed postdoctoral studies as a Fulbright scholar at UCSF and as a Royal Commission Fellow in the ICRF before joining RPR in 1991. In 1998 he joined Eli Lilly to lead the European modelling group, and then in 2004 moved to his current role. He has authored over 80 papers and patents, and is a fellow of the Royal Society of Chemistry. H-index > 32
Charly Chahwan
Jean-Christophe Harmange
